Gilead Sciences Inc (NASDAQ:GILD) announced new data from an interim analysis of its ongoing, Phase 2/3 study of Veklury (remdesivir) in pediatric patients hospitalized with COVID-19.
- The data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022).
- The latest data demonstrate that Veklury was generally well-tolerated among pediatric patients hospitalized with COVID-19, with a high proportion of participants showing clinical improvement and recovery.
- Related: Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron.
- Overall, no new safety findings for Veklury were noted, and 85% of patients showed clinical improvement based on the clinical ordinal scale, and the recovery rate was 83% at the last assessment (N=53).
- In January, the FDA expanded the pediatric Emergency Use Authorization (EUA) of Veklury to include non-hospitalized pediatric patients.
- Also Read: Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates.
- Price Action: GILD shares are down 0.52% at $61.75 during the premarket session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
